Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,905 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Finn RS, et al. Among authors: kubota t. J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27. J Clin Oncol. 2020. PMID: 32716739 Free PMC article. Clinical Trial.
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
Zheng X, Xu Z, Ji Q, Ge M, Shi F, Qin J, Wang F, Chen G, Zhang Y, Huang R, Tan J, Huang T, Li S, Lv Z, Lin Y, Guo Z, Kubota T, Suzuki T, Ikezawa H, Gao M. Zheng X, et al. Among authors: kubota t. Clin Cancer Res. 2021 Oct 15;27(20):5502-5509. doi: 10.1158/1078-0432.CCR-21-0761. Epub 2021 Jul 29. Clin Cancer Res. 2021. PMID: 34326132 Free PMC article. Clinical Trial.
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
Kitano S, Fujiwara Y, Shimizu T, Iwasa S, Yonemori K, Kondo S, Shimomura A, Koyama T, Ebata T, Ikezawa H, Hayata N, Minoshima Y, Miura T, Kubota T, Yamamoto N. Kitano S, et al. Among authors: kubota t. Cancer Chemother Pharmacol. 2022 Dec;90(6):523-529. doi: 10.1007/s00280-022-04480-w. Epub 2022 Oct 26. Cancer Chemother Pharmacol. 2022. PMID: 36289094 Clinical Trial.
A novel semi-quantitative scoring method for CD8+ tumor-infiltrating lymphocytes based on infiltration sites in gastric cancer.
Nakabayashi Y, Kiuchi J, Kubota T, Ohashi T, Nishibeppu K, Imamura T, Nanishi K, Shimizu H, Arita T, Yamamoto Y, Konishi H, Morimura R, Komatsu S, Shiozaki A, Ikoma H, Kuriu Y, Fujiwara H, Tsuda H, Otsuji E. Nakabayashi Y, et al. Among authors: kubota t. Am J Cancer Res. 2024 Dec 25;14(12):5965-5986. doi: 10.62347/JKCU5881. eCollection 2024. Am J Cancer Res. 2024. PMID: 39803654 Free PMC article.
Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis.
Watanabe G, Takai Y, Nagane Y, Kubota T, Yasuda M, Akamine H, Onishi Y, Uzawa A, Kawaguchi N, Masuda M, Konno S, Amino I, Minami N, Kimura T, Samukawa M, Sugimoto T, Suzuki Y, Takahashi MP, Suzuki S, Murai H, Aoki M, Utsugisawa K. Watanabe G, et al. Among authors: kubota t. Front Immunol. 2024 Dec 23;15:1502721. doi: 10.3389/fimmu.2024.1502721. eCollection 2024. Front Immunol. 2024. PMID: 39763650 Free PMC article.
3,905 results